CSF2 and neoplasm: Engineered OVs expressing ICIs (e.g., anti-PD-1, anti-CTLA-4) or immunostimulatory cytokines (e.g., GM-CSF) can counteract these signals, reinvigorate T-cell function, and enhance both viral oncolysis and immune-mediated tumor clearance (40, 41).